TRVI Stock Analysis: Trevi Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.124m USD | 12M Return: 17.1% | US89532M1018 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 21.0M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.5 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Trevi Therapeutics, Inc. (NASDAQ: TRVI) is a U.S.-based, clinical-stage biopharmaceutical company headquartered in New Haven, Connecticut, focused on developing therapies for chronic cough associated with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. Its lead investigational product, Haduvio, is an oral extended-release formulation of nalbuphine, currently in a Phase 2b trial for chronic cough in IPF patients and a Phase 2a trial for refractory chronic cough. The company also holds a license agreement with Keenova Therapeutics plc covering nalbuphine hydrochloride formulations, and was incorporated in 2011 with its IPO completed in May 2019.
As a clinical-stage biopharmaceutical firm operating in the Pharmaceuticals sub-industry, Trevi Therapeutics has not yet commercialized a product and relies on R&D progress, licensing arrangements, and capital markets to fund its pipeline. The companys focus on repurposing an established opioid analgesic (nalbuphine) for chronic cough targets indications with limited existing treatment options.
- Haduvio phase 2b IPF chronic cough data readout approaches
- Refractory chronic cough phase 2a Haduvio trial results expected
- Lillys gefapixant approval threatens Haduvio competitive positioning
- Cash runway supports Haduvio development through key clinical catalysts
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.20 > 0.02 and ΔFCF/TA 2.24 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.20 > 3% & CFO -61.4m > Net Income -60.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 38.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (142.5m) vs 12m ago -1.78% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.07%; Δ -0.07% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.96 (Total Current Assets 305.8m - Total Current Liabilities 7.87m) / Total Assets 310.8m |
| B: -1.23 (Retained Earnings -382.2m / Total Assets 310.8m) |
| C: -0.25 (EBIT TTM -63.8m / Avg Total Assets 255.1m) |
| D: 37.58 (Book Value of Equity 302.8m / Total Liabilities 8.06m) |
| Altman-Z'' = 40.06 = AAA |
As of November 17, 2026, the stock is trading at USD 13.29 with a total of 1,635,715 shares traded. Over the past week, the price has changed by -13.19%, over one month by +11.87%, over three months by -28.08% and over the past year by +17.09%.
Current recommended Stop Loss: 12.10 (which is 9% or 1.3 ATR below the current price).
Trevi Therapeutics has received a consensus analysts rating of 4.82. Therefore, it is recommended to buy TRVI.
- StrongBuy: 9
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 28.2 | 112% |
P/B = 6.7846
Revenue TTM = 0.0 USD
EBIT TTM = -63.8m USD
EBITDA TTM = -63.7m USD
Long Term Debt = 187k USD (estimated: total debt 527k - short term 340k)
Short Term Debt = 340k USD (from shortTermDebt, last quarter)
Debt = 527k USD (from shortLongTermDebtTotal, last quarter) (leases 527k already included)
Net Debt = -298.9m USD (calculated: Debt 527k - CCE 299.4m)
Enterprise Value = 1.83b USD (2.12b + Debt 527k - CCE 299.4m)
Interest Coverage Ratio = unknown (Ebit TTM -63.8m / Interest Expense TTM 0.0)
EV/FCF = -29.59x (Enterprise Value 1.83b / FCF TTM -61.7m)
FCF Yield = -3.38% (FCF TTM -61.7m / Enterprise Value 1.83b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 132k) / Revenue TTM)
Tobins Q-Ratio = 5.87 (Enterprise Value 1.83b / Total Assets 310.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 527k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -50.4m (EBIT -63.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 38.86 (Total Current Assets 305.8m / Total Current Liabilities 7.87m)
Debt / Equity = 0.00 (Debt 527k / totalStockholderEquity, last quarter 302.8m)
Debt / EBITDA = 4.69 (negative EBITDA) (Net Debt -298.9m / EBITDA -63.7m)
Debt / FCF = 4.85 (negative FCF - burning cash) (Net Debt -298.9m / FCF TTM -61.7m)
Total Stockholder Equity = 244.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -23.82% (Net Income -60.8m / Total Assets 310.8m)
RoE = -24.81% (Net Income TTM -60.8m / Total Stockholder Equity 244.9m)
RoCE = -26.05% (EBIT -63.8m / Capital Employed (Equity 244.9m + L.T.Debt 187k))
RoIC = -16.63% (negative operating profit) (NOPAT -50.4m / Invested Capital 303.3m)
WACC = 5.22% (E(2.12b)/V(2.12b) * Re(5.22%) + D(527k)/V(2.12b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 5.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.79 | Cagr: 22.32%
[DCF] Fair Price = unknown (Cash Flow -61.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.16 | Chg30d=+0.00% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=-0.49 | Chg30d=-2.76% | Revisions=-55% | GrowthEPS=-53.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.59 | Chg30d=-2.60% | Revisions=-44% | GrowthEPS=-20.3% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -59% (up=2, down=12)